MRTX
Closed
Mirati Ther
58.7
-0.1 (-0.17%)
Last Update: 23 Jan 2024 17:30:00
Yesterday: 58.8
Day's Range: 58.7 - 58.7
Send
sign up or login to leave a comment!
When Written:
38.46
Mirati Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing targeted oncology therapies. The company's lead product candidate, MRTX849, is a small molecule inhibitor of KRAS G12C, a genetic mutation that is frequently found in various types of cancer. Mirati is also developing other small molecule inhibitors targeting genetic mutations in cancer, including MRTX1133 and MRTX1257. The company is headquartered in San Diego, California and was founded in 1995. Mirati went public in 2013 and is traded on the NASDAQ stock exchange under the ticker symbol MRTX.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!
When Written:
38.46
Mirati Therapeutics is a biopharmaceutical company that focuses on developing targeted oncology therapies. The company's pipeline includes drug candidates that target specific genetic mutations and signaling pathways that are implicated in cancer growth and progression. Mirati's lead drug candidate, adagrasib (MRTX849), is a small molecule inhibitor of KRAS G12C, a common driver mutation in non-small cell lung cancer and other solid tumors. The company is also developing drug candidates that target other oncogenic drivers, including KRAS G12D, SHP2, and EGFR exon 20 insertions. Mirati was founded in 1995 and is headquartered in San Diego, California.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








